SELLAS Life Sciences Group, Inc. (SLS)
USD 1.04
(-5.91%)
USD 1.04
(-5.91%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | -1.72 Million USD | 89.34% |
| 2022 | -16.18 Million USD | 21.25% |
| 2021 | -20.54 Million USD | 40.12% |
| 2020 | -34.31 Million USD | -385.99% |
| 2019 | -7.06 Million USD | -32.28% |
| 2018 | -5.33 Million USD | -161.56% |
| 2017 | 8.66 Million USD | 614.18% |
| 2016 | -1.68 Million USD | 93.25% |
| 2015 | -24.99 Million USD | -63.9% |
| 2014 | -15.24 Million USD | 59.73% |
| 2013 | -37.86 Million USD | -15.61% |
| 2012 | -32.75 Million USD | -201.4% |
| 2011 | -10.86 Million USD | -59.33% |
| 2010 | -6.82 Million USD | -21.87% |
| 2009 | -5.59 Million USD | 43.1% |
| 2008 | -9.83 Million USD | -457.86% |
| 2007 | -1.76 Million USD | -88050.0% |
| 2006 | -2000.00 USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -17.71 Million USD | -927.49% |
| 2024 Q2 | -8.55 Million USD | 52.27% |
| 2023 Q2 | -13.05 Million USD | 43.36% |
| 2023 Q4 | -1.72 Million USD | 48.15% |
| 2023 FY | -1.72 Million USD | 89.34% |
| 2023 Q3 | -3.32 Million USD | 74.54% |
| 2023 Q1 | -23.05 Million USD | -42.48% |
| 2022 Q3 | -20.31 Million USD | 21.46% |
| 2022 Q4 | -16.18 Million USD | 20.34% |
| 2022 FY | -16.18 Million USD | 21.25% |
| 2022 Q1 | -13.04 Million USD | 36.52% |
| 2022 Q2 | -25.86 Million USD | -98.28% |
| 2021 Q3 | -25.42 Million USD | 12.37% |
| 2021 Q4 | -20.54 Million USD | 19.18% |
| 2021 FY | -20.54 Million USD | 40.12% |
| 2021 Q1 | -27.08 Million USD | 21.06% |
| 2021 Q2 | -29.01 Million USD | -7.13% |
| 2020 Q1 | -6.62 Million USD | 6.19% |
| 2020 FY | -34.31 Million USD | -385.99% |
| 2020 Q2 | -2.33 Million USD | 64.79% |
| 2020 Q3 | -7.19 Million USD | -208.49% |
| 2020 Q4 | -34.31 Million USD | -376.94% |
| 2019 Q2 | -12.36 Million USD | -487.22% |
| 2019 Q1 | -2.1 Million USD | 60.56% |
| 2019 Q4 | -7.06 Million USD | 19.89% |
| 2019 FY | -7.06 Million USD | -32.28% |
| 2019 Q3 | -8.81 Million USD | 28.7% |
| 2018 Q2 | 6.43 Million USD | 3.68% |
| 2018 Q4 | -5.33 Million USD | 46.05% |
| 2018 Q3 | -9.89 Million USD | -253.84% |
| 2018 FY | -5.33 Million USD | -161.56% |
| 2018 Q1 | 6.2 Million USD | -28.46% |
| 2017 FY | 8.66 Million USD | 614.18% |
| 2017 Q4 | 8.66 Million USD | 1265.19% |
| 2017 Q3 | -744 Thousand USD | 85.26% |
| 2017 Q2 | -5.04 Million USD | 66.44% |
| 2017 Q1 | -15.04 Million USD | -792.23% |
| 2016 Q4 | -1.68 Million USD | -112.88% |
| 2016 Q3 | -792 Thousand USD | -122.2% |
| 2016 Q2 | 3.56 Million USD | 111.52% |
| 2016 Q1 | -30.96 Million USD | -23.92% |
| 2016 FY | -1.68 Million USD | 93.25% |
| 2015 Q3 | -29.12 Million USD | 24.66% |
| 2015 FY | -24.99 Million USD | -63.9% |
| 2015 Q4 | -24.99 Million USD | 14.18% |
| 2015 Q1 | -45.33 Million USD | -197.3% |
| 2015 Q2 | -38.65 Million USD | 14.73% |
| 2014 FY | -15.24 Million USD | 59.73% |
| 2014 Q4 | -15.24 Million USD | 0.76% |
| 2014 Q2 | -29.05 Million USD | 31.49% |
| 2014 Q3 | -15.36 Million USD | 47.13% |
| 2014 Q1 | -42.41 Million USD | -12.02% |
| 2013 Q3 | -41.56 Million USD | -271.92% |
| 2013 FY | -37.86 Million USD | -15.61% |
| 2013 Q2 | -11.17 Million USD | 35.86% |
| 2013 Q1 | -17.42 Million USD | 46.8% |
| 2013 Q4 | -37.86 Million USD | 8.9% |
| 2012 Q1 | -7.64 Million USD | 29.68% |
| 2012 Q2 | -19.17 Million USD | -150.9% |
| 2012 FY | -32.75 Million USD | -201.4% |
| 2012 Q4 | -32.75 Million USD | -113.13% |
| 2012 Q3 | -15.36 Million USD | 19.85% |
| 2011 Q2 | -17.86 Million USD | -62.06% |
| 2011 Q4 | -10.86 Million USD | 28.11% |
| 2011 FY | -10.86 Million USD | -59.33% |
| 2011 Q1 | -11.02 Million USD | -61.63% |
| 2011 Q3 | -15.11 Million USD | 15.39% |
| 2010 FY | -6.82 Million USD | -21.87% |
| 2010 Q1 | -14.75 Million USD | -163.6% |
| 2010 Q3 | -2.74 Million USD | 45.27% |
| 2010 Q2 | -5 Million USD | 66.05% |
| 2010 Q4 | -6.82 Million USD | -148.81% |
| 2009 Q1 | -7.15 Million USD | 27.25% |
| 2009 Q4 | -5.59 Million USD | 37.01% |
| 2009 FY | -5.59 Million USD | 43.1% |
| 2009 Q2 | -4.33 Million USD | 39.39% |
| 2009 Q3 | -8.88 Million USD | -104.84% |
| 2008 Q3 | -3.65 Million USD | 59.34% |
| 2008 Q1 | -9.85 Million USD | -459.1% |
| 2008 FY | -9.83 Million USD | -457.86% |
| 2008 Q2 | -8.99 Million USD | 8.8% |
| 2008 Q4 | -9.83 Million USD | -169.08% |
| 2007 Q4 | -1.76 Million USD | 25.11% |
| 2007 FY | -1.76 Million USD | -88050.0% |
| 2007 Q3 | -2.35 Million USD | 0.0% |
| 2006 FY | -2000.00 USD | 0.0% |
| 2006 Q4 | -2000.00 USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| AbCellera Biologics Inc. | -55.94 Million USD | 96.918% |
| Alkermes plc | -166.73 Million USD | 98.966% |
| Agenus Inc. | 274.13 Million USD | 100.629% |
| Alnylam Pharmaceuticals, Inc. | 1.86 Billion USD | 100.092% |
| Aptorum Group Limited | 1.35 Million USD | 227.041% |
| Ardelyx, Inc. | 34.51 Million USD | 104.995% |
| Arrowhead Pharmaceuticals, Inc. | 4.28 Million USD | 140.28% |
| Bicycle Therapeutics plc | -481.46 Million USD | 99.642% |
| BioXcel Therapeutics, Inc. | 36.16 Million USD | 104.767% |
| ChromaDex Corporation | -24.04 Million USD | 92.831% |
| Chimerix, Inc. | -25.51 Million USD | 93.244% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | 124.741% |
| Caribou Biosciences, Inc. | -23.67 Million USD | 92.719% |
| CRISPR Therapeutics AG | -150.84 Million USD | 98.857% |
| Precision BioSciences, Inc. | -85.41 Million USD | 97.982% |
| Dyadic International, Inc. | -6.37 Million USD | 72.97% |
| Eton Pharmaceuticals, Inc. | -15.93 Million USD | 89.18% |
| Fortress Biotech, Inc. | 7.66 Million USD | 122.492% |
| Lantern Pharma Inc. | -21.7 Million USD | 92.056% |
| HOOKIPA Pharma Inc. | -110.53 Million USD | 98.44% |
| Inhibikase Therapeutics, Inc. | -8.54 Million USD | 79.82% |
| Incyte Corporation | -3.17 Billion USD | 99.946% |
| IO Biotech, Inc. | -140.69 Million USD | 98.775% |
| Jaguar Health, Inc. | 29.39 Million USD | 105.866% |
| Novavax, Inc. | -298.29 Million USD | 99.422% |
| Janux Therapeutics, Inc. | 5.33 Million USD | 132.303% |
| Opthea Limited | 28.15 Million USD | 106.123% |
| Ligand Pharmaceuticals Incorporated | -16.78 Million USD | 89.731% |
| ContextLogic Inc. | -232 Million USD | 99.257% |
| MiMedx Group, Inc. | -33.9 Million USD | 94.915% |
| Pyxis Oncology, Inc. | 10.19 Million USD | 116.91% |
| TransCode Therapeutics, Inc. | -2.31 Million USD | 25.594% |
| NextCure, Inc. | -6.47 Million USD | 73.383% |
| Ocuphire Pharma, Inc. | -50.5 Million USD | 96.586% |
| Oncternal Therapeutics, Inc. | -6.37 Million USD | 72.974% |
| Outlook Therapeutics, Inc. | 12.16 Million USD | 114.174% |
| Vaxcyte, Inc. | -368.22 Million USD | 99.532% |
| PDS Biotechnology Corporation | -32.7 Million USD | 94.729% |
| Madrigal Pharmaceuticals, Inc. | 17.27 Million USD | 109.978% |
| Pharming Group N.V. | 109.8 Million USD | 101.57% |
| Pieris Pharmaceuticals, Inc. | -17.39 Million USD | 90.09% |
| Avidity Biosciences, Inc. | -175.23 Million USD | 99.016% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 90.691% |
| Reviva Pharmaceuticals Holdings, Inc. | -18.51 Million USD | 90.691% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 75.718% |
| Sol-Gel Technologies Ltd. | -5.86 Million USD | 70.58% |
| Acelyrin, Inc. | -216.9 Million USD | 99.205% |
| Salarius Pharmaceuticals, Inc. | -5.61 Million USD | 69.271% |
| Summit Therapeutics Inc. | 34.67 Million USD | 104.972% |
| Sensei Biotherapeutics, Inc. | -6.8 Million USD | 74.658% |
| Senti Biosciences, Inc. | 1.74 Million USD | 199.08% |
| Stoke Therapeutics, Inc. | -184.6 Million USD | 99.066% |
| Syros Pharmaceuticals, Inc. | -77.45 Million USD | 97.774% |
| Alaunos Therapeutics, Inc. | -6.06 Million USD | 71.561% |
| Telomir Pharmaceuticals, Inc. Common Stock | 99.76 Thousand USD | 1827.992% |
| Entrada Therapeutics, Inc. | 628 Thousand USD | 374.522% |
| VistaGen Therapeutics, Inc. | -117.04 Million USD | 98.527% |
| Wave Life Sciences Ltd. | -168.23 Million USD | 98.975% |
| Sorrento Therapeutics, Inc. | 110.87 Million USD | 101.555% |
| TRACON Pharmaceuticals, Inc. | -7.59 Million USD | 77.304% |
| Barinthus Biotherapeutics plc | -129.11 Million USD | 98.665% |
| Psyence Biomedical Ltd. | 6.89 Million USD | 125.005% |
| Phathom Pharmaceuticals, Inc. | -242.36 Million USD | 99.289% |
| Immix Biopharma, Inc. | -17.5 Million USD | 90.154% |
| Keros Therapeutics, Inc. | -316.7 Million USD | 99.456% |
| MEI Pharma, Inc. | -3.7 Million USD | 53.468% |
| Windtree Therapeutics, Inc. | 12.51 Million USD | 113.78% |
| Xeris Biopharma Holdings, Inc. | 161.74 Million USD | 101.066% |
| Rigel Pharmaceuticals, Inc. | 27.79 Million USD | 106.203% |
| Fortress Biotech, Inc. | 7.66 Million USD | 122.492% |
| Precigen, Inc. | -481 Thousand USD | -258.42% |
| Clearside Biomedical, Inc. | 14.08 Million USD | 112.243% |
| AlloVir, Inc. | -62.69 Million USD | 97.25% |
| C4 Therapeutics, Inc. | -55.61 Million USD | 96.9% |
| Fate Therapeutics, Inc. | 61.66 Million USD | 102.796% |
| ImmuCell Corporation | 10.99 Million USD | 115.686% |
| IDEAYA Biosciences, Inc. | -154.14 Million USD | 98.882% |
| Onconetix, Inc. | 5.33 Million USD | 132.336% |
| PureTech Health plc | -167.19 Million USD | 98.969% |
| VYNE Therapeutics Inc. | -30.46 Million USD | 94.34% |
| Elevation Oncology, Inc. | -19.11 Million USD | 90.982% |
| Kintara Therapeutics, Inc. | -4.9 Million USD | 64.881% |
| Seer, Inc. | -4.24 Million USD | 59.34% |
| Verrica Pharmaceuticals Inc. | -24.03 Million USD | 92.828% |
| Innoviva, Inc. | 255.56 Million USD | 100.675% |
| Aadi Bioscience, Inc. | -55.86 Million USD | 96.914% |
| ESSA Pharma Inc. | -33.62 Million USD | 94.872% |
| GlycoMimetics, Inc. | -40.98 Million USD | 95.794% |
| GT Biopharma, Inc. | -1.02 Million USD | -68.854% |
| Inhibrx Biosciences, Inc. | -67.78 Million USD | 97.457% |
| Akebia Therapeutics, Inc. | 61.25 Million USD | 102.814% |
| Catalyst Pharmaceuticals, Inc. | -134.07 Million USD | 98.714% |
| Longboard Pharmaceuticals, Inc. | -13.85 Million USD | 87.558% |
| Orchestra BioMed Holdings, Inc. | -28.87 Million USD | 94.029% |
| Alzamend Neuro, Inc. | -75.33 Thousand USD | -2188.475% |
| Rocket Pharmaceuticals, Inc. | -30.86 Million USD | 94.414% |
| Aptose Biosciences Inc. | -8.19 Million USD | 78.962% |
| ZyVersa Therapeutics, Inc. | -3.12 Million USD | 44.903% |
| Soligenix, Inc. | -4.95 Million USD | 65.183% |
| Century Therapeutics, Inc. | 847 Thousand USD | 303.542% |
| Kura Oncology, Inc. | -20.11 Million USD | 91.431% |
| TScan Therapeutics, Inc. | -40.92 Million USD | 95.788% |
| Intensity Therapeutics, Inc. | -8.39 Million USD | 79.471% |
| Ocean Biomedical, Inc. | 1.82 Million USD | 194.637% |
| CytomX Therapeutics, Inc. | -3.19 Million USD | 46.074% |
| Autolus Therapeutics plc | -186.59 Million USD | 99.076% |
| Mineralys Therapeutics, Inc. | -49.3 Million USD | 96.503% |
| EyePoint Pharmaceuticals, Inc. | -275.79 Million USD | 99.375% |
| Eterna Therapeutics Inc. | 34.26 Million USD | 105.031% |
| Adaptive Biotechnologies Corporation | 164.36 Million USD | 101.049% |
| GRI Bio, Inc. | -1.79 Million USD | 3.902% |
| Xenetic Biosciences, Inc. | -8.98 Million USD | 80.808% |
| Tenaya Therapeutics, Inc. | -33.25 Million USD | 94.816% |
| IGM Biosciences, Inc. | -72.6 Million USD | 97.626% |
| INmune Bio, Inc. | -25.41 Million USD | 93.216% |
| Heron Therapeutics, Inc. | 150.95 Million USD | 101.142% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 96.597% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 89.39% |
| Entero Therapeutics, Inc. | -2.88 Million USD | 40.241% |
| Milestone Pharmaceuticals Inc. | 38.01 Million USD | 104.535% |
| X4 Pharmaceuticals, Inc. | -41.18 Million USD | 95.814% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 105.407% |
| Coherus BioSciences, Inc. | 377.95 Million USD | 100.456% |
| Verastem, Inc. | -37.27 Million USD | 95.375% |
| Abeona Therapeutics Inc. | -9.07 Million USD | 80.999% |
| Pliant Therapeutics, Inc. | -51.86 Million USD | 96.676% |
| Tonix Pharmaceuticals Holding Corp. | -15.13 Million USD | 88.609% |
| Histogen Inc. | -7.48 Million USD | 76.973% |
| Aprea Therapeutics, Inc. | -21.6 Million USD | 92.021% |
| Surrozen, Inc. | -32.66 Million USD | 94.722% |
| Organovo Holdings, Inc. | -1.5 Million USD | -14.399% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 58.986% |
| Ovid Therapeutics Inc. | 18.96 Million USD | 109.093% |
| Panbela Therapeutics, Inc. | 2.61 Million USD | 165.902% |
| CASI Pharmaceuticals, Inc. | 4.15 Million USD | 141.482% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.38 Million USD | 79.43% |
| Centessa Pharmaceuticals plc | -43.44 Million USD | 96.031% |
| Hepion Pharmaceuticals, Inc. | -14.57 Million USD | 88.173% |
| Arcturus Therapeutics Holdings Inc. | -316.78 Million USD | 99.456% |
| BioRestorative Therapies, Inc. | -722.06 Thousand USD | -138.761% |
| Apollomics, Inc. | -27.39 Million USD | 93.707% |
| Amarin Corporation plc | -191.04 Million USD | 99.098% |
| Mesoblast Limited | 55.96 Million USD | 103.081% |
| Turnstone Biologics Corp. | -14.58 Million USD | 88.179% |
| Kymera Therapeutics, Inc. | -25.29 Million USD | 93.184% |
| Synaptogenix, Inc. | -28.66 Million USD | 93.985% |
| Tiziana Life Sciences Ltd | -936 Thousand USD | -84.188% |
| Aurinia Pharmaceuticals Inc. | 48.73 Million USD | 103.538% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -99.979% |
| Monopar Therapeutics Inc. | -7.26 Million USD | 76.273% |
| Exelixis, Inc. | -73.05 Million USD | 97.64% |
| Better Therapeutics, Inc. | -860 Thousand USD | -100.465% |
| Nurix Therapeutics, Inc. | -24.01 Million USD | 92.821% |
| Apellis Pharmaceuticals, Inc. | -241.37 Million USD | 99.286% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 334.218% |
| Dermata Therapeutics, Inc. | -7.43 Million USD | 76.822% |
| Aridis Pharmaceuticals, Inc. | 1.25 Million USD | 237.48% |
| Gritstone bio, Inc. | 39.49 Million USD | 104.366% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 97.95% |
| TNF Pharmaceuticals, Inc. | -2.63 Million USD | 34.502% |
| Avid Bioservices, Inc. | 169.72 Million USD | 101.016% |
| Insmed Incorporated | 721.62 Million USD | 100.239% |
| Virpax Pharmaceuticals, Inc. | -9.14 Million USD | 81.141% |
| MediWound Ltd. | -5.32 Million USD | 67.606% |
| OmniAb, Inc. | 9.2 Million USD | 118.733% |
| Alector, Inc. | -35.63 Million USD | 95.162% |
| Seres Therapeutics, Inc. | 85.97 Million USD | 102.005% |
| Checkpoint Therapeutics, Inc. | -4.92 Million USD | 65.016% |
| Viracta Therapeutics, Inc. | 13.23 Million USD | 113.022% |
| Zai Lab Limited | -775 Million USD | 99.778% |
| Revance Therapeutics, Inc. | 340.55 Million USD | 100.506% |
| Aura Biosciences, Inc. | -21.52 Million USD | 91.991% |
| Lyell Immunopharma, Inc. | -82.48 Million USD | 97.91% |
| Immunic, Inc. | -45.34 Million USD | 96.198% |
| Tarsus Pharmaceuticals, Inc. | -193.21 Million USD | 99.108% |
| Veracyte, Inc. | -203.82 Million USD | 99.154% |
| InMed Pharmaceuticals Inc. | 638.29 Million USD | 100.27% |
| FibroGen, Inc. | 56.76 Million USD | 103.037% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 119.36% |
| Adial Pharmaceuticals, Inc. | -2.82 Million USD | 39.018% |
| Sonnet BioTherapeutics Holdings, Inc. | -2.07 Million USD | 16.729% |
| Jazz Pharmaceuticals plc | 4.59 Billion USD | 100.038% |
| Cyclacel Pharmaceuticals, Inc. | -3.34 Million USD | 48.399% |
| Amylyx Pharmaceuticals, Inc. | -165.96 Million USD | 98.961% |
| TG Therapeutics, Inc. | 17.86 Million USD | 109.652% |
| Galecto, Inc. | -21.21 Million USD | 91.874% |
| Calithera Biosciences, Inc. | -23.78 Million USD | 92.752% |
| Fortrea Holdings Inc. | 1.56 Billion USD | 100.11% |
| KalVista Pharmaceuticals, Inc. | -24.47 Million USD | 92.955% |
| Aptevo Therapeutics Inc. | -11.5 Million USD | 85.018% |
| XBiotech Inc. | -200.02 Million USD | 99.138% |
| Jasper Therapeutics, Inc. | -84.1 Million USD | 97.95% |
| Lyra Therapeutics, Inc. | 4.52 Million USD | 138.074% |
| Foghorn Therapeutics Inc. | -35.26 Million USD | 95.111% |
| Y-mAbs Therapeutics, Inc. | -77.21 Million USD | 97.767% |
| Theravance Biopharma, Inc. | 5.69 Million USD | 130.293% |
| Ultragenyx Pharmaceutical Inc. | -170.41 Million USD | 98.988% |
| Metagenomi, Inc. Common Stock | -92.37 Million USD | 98.134% |
| Vaxxinity, Inc. | 10.13 Million USD | 117.015% |
| BioCryst Pharmaceuticals, Inc. | 736.26 Million USD | 100.234% |
| Gain Therapeutics, Inc. | -10.76 Million USD | 83.989% |
| Cartesian Therapeutics, Inc. | -65.95 Million USD | 97.386% |
| NexImmune, Inc. | -3.13 Million USD | 44.984% |
| Creative Medical Technology Holdings, Inc. | -3.45 Million USD | 50.068% |
| Marker Therapeutics, Inc. | -15.11 Million USD | 88.591% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 93.638% |
| Chemomab Therapeutics Ltd. | -8.97 Million USD | 80.793% |
| Scopus BioPharma Inc. | -124.57 Thousand USD | -1283.905% |
| RAPT Therapeutics, Inc. | -40.57 Million USD | 95.751% |
| Ainos, Inc. | 4.07 Million USD | 142.276% |
| Pluri Inc. | 22.82 Million USD | 107.552% |
| Prothena Corporation plc | -608.34 Million USD | 99.717% |
| Adaptimmune Therapeutics plc | -118.75 Million USD | 98.548% |
| Celularity Inc. | 65.19 Million USD | 102.645% |
| Rallybio Corporation | -24.1 Million USD | 92.847% |
| Cue Biopharma, Inc. | -33.81 Million USD | 94.902% |
| MeiraGTx Holdings plc | -40.3 Million USD | 95.722% |
| Omeros Corporation | 331.17 Million USD | 100.521% |
| Humacyte, Inc. | -22.48 Million USD | 92.333% |
| Immunocore Holdings plc | -358.59 Million USD | 99.519% |
| Cocrystal Pharma, Inc. | -24.57 Million USD | 92.985% |
| Cidara Therapeutics, Inc. | -30.9 Million USD | 94.421% |
| Blueprint Medicines Corporation | 702.83 Million USD | 100.245% |
| CalciMedica, Inc. | -5.53 Million USD | 68.825% |
| Cabaletta Bio, Inc. | -188.22 Million USD | 99.084% |
| Marinus Pharmaceuticals, Inc. | -10.21 Million USD | 83.121% |
| Scholar Rock Holding Corporation | -40.03 Million USD | 95.694% |
| Sana Biotechnology, Inc. | -33.25 Million USD | 94.816% |
| Pulmatrix, Inc. | -10.41 Million USD | 83.45% |
| Elicio Therapeutics, Inc. | -5.97 Million USD | 71.156% |
| Vigil Neuroscience, Inc. | -38.14 Million USD | 95.48% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 98.452% |
| Adlai Nortye Ltd. American Depositary Shares | -59.94 Million USD | 97.124% |
| Cytokinetics, Incorporated | 642.37 Million USD | 100.268% |
| Eloxx Pharmaceuticals, Inc. | -5.82 Million USD | 70.393% |
| Nutriband Inc. | -251.65 Thousand USD | -585.059% |
| Protara Therapeutics, Inc. | -34.11 Million USD | 94.947% |
| Vor Biopharma Inc. | 4.3 Million USD | 140.093% |
| Roivant Sciences Ltd. | -6.03 Billion USD | 99.971% |
| Evogene Ltd. | -19.63 Million USD | 91.219% |
| ProKidney Corp. | -56.23 Million USD | 96.934% |
| Applied Therapeutics, Inc. | -48.67 Million USD | 96.458% |
| Hoth Therapeutics, Inc. | -9.23 Million USD | 81.336% |
| BridgeBio Pharma, Inc. | 1.36 Billion USD | 100.126% |
| CorMedix Inc. | -43.05 Million USD | 95.996% |
| BioLineRx Ltd. | 7.33 Million USD | 123.501% |
| Tango Therapeutics, Inc. | -27.46 Million USD | 93.723% |
| Galectin Therapeutics Inc. | 46.14 Million USD | 103.736% |
| Atai Life Sciences N.V. | -28.55 Million USD | 93.963% |
| Renovaro Biosciences Inc. | 2.23 Million USD | 177.291% |
| Aerovate Therapeutics, Inc. | -22.81 Million USD | 92.444% |
| Zentalis Pharmaceuticals, Inc. | 17.73 Million USD | 109.721% |
| Sagimet Biosciences Inc. | -75.07 Million USD | 97.704% |
| MediciNova, Inc. | -50.78 Million USD | 96.605% |
| Praxis Precision Medicines, Inc. | -78.8 Million USD | 97.812% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -7563.925% |
| GeoVax Labs, Inc. | -6.45 Million USD | 73.282% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 99.137% |
| Biomea Fusion, Inc. | -166.57 Million USD | 98.965% |
| PTC Therapeutics, Inc. | -178.97 Million USD | 99.037% |
| Mereo BioPharma Group plc | -51.46 Million USD | 96.65% |
| Cullinan Oncology, Inc. | -94.84 Million USD | 98.182% |
| Syndax Pharmaceuticals, Inc. | -293.75 Million USD | 99.413% |
| Absci Corporation | -72.59 Million USD | 97.625% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 137.757% |
| 4D Molecular Therapeutics, Inc. | -234.43 Million USD | 99.265% |
| Dyne Therapeutics, Inc. | -94.21 Million USD | 98.17% |
| Kiniksa Pharmaceuticals, Ltd. | -95.69 Million USD | 98.198% |
| Ventyx Biosciences, Inc. | -39.07 Million USD | 95.588% |
| Allakos Inc. | -24.97 Million USD | 93.097% |
| Imunon, Inc. | -4.21 Million USD | 59.087% |
| Fulcrum Therapeutics, Inc. | -14.74 Million USD | 88.306% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 98.727% |
| BioAtla, Inc. | -109.01 Million USD | 98.419% |
| NLS Pharmaceutics AG | 736.06 Thousand USD | 334.218% |
| Bio-Path Holdings, Inc. | -939 Thousand USD | -83.6% |
| Allogene Therapeutics, Inc. | 11.96 Million USD | 114.407% |
| Larimar Therapeutics, Inc. | -21.2 Million USD | 91.869% |
| XOMA Corporation | -29 Million USD | 94.055% |
| Kezar Life Sciences, Inc. | -16.56 Million USD | 89.589% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 80.878% |
| aTyr Pharma, Inc. | -7.44 Million USD | 76.856% |
| Aligos Therapeutics, Inc. | -124.63 Million USD | 98.617% |
| Akero Therapeutics, Inc. | -208.16 Million USD | 99.172% |
| Viridian Therapeutics, Inc. | -81.77 Million USD | 97.892% |
| Eliem Therapeutics, Inc. | -92.76 Million USD | 98.142% |
| EyeGate Pharmaceuticals, Inc. | -859.18 Thousand USD | -100.656% |
| Akari Therapeutics, Plc | -3.84 Million USD | 55.163% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 206.23% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 100.125% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -45.101% |
| UroGen Pharma Ltd. | 4.39 Million USD | 139.262% |
| Sutro Biopharma, Inc. | 113.48 Million USD | 101.519% |
| ZIVO Bioscience, Inc. | 71.96 Thousand USD | 2495.709% |
| Orgenesis Inc. | 21.78 Million USD | 107.914% |
| Entera Bio Ltd. | -10.62 Million USD | 83.78% |
| GH Research PLC | -78.07 Million USD | 97.792% |
| Lisata Therapeutics, Inc. | -22.28 Million USD | 92.265% |
| Reneo Pharmaceuticals, Inc. | -26.65 Million USD | 93.533% |
| Xencor, Inc. | 29.64 Million USD | 105.816% |
| 60 Degrees Pharmaceuticals, Inc. | -1.96 Million USD | 12.479% |
| Replimune Group, Inc. | 1.41 Million USD | 222.096% |
| Coeptis Therapeutics Holdings, Inc. | -244.9 Thousand USD | -603.938% |
| Vanda Pharmaceuticals Inc. | -126.41 Million USD | 98.636% |
| Lexaria Bioscience Corp. | -1.18 Million USD | -45.101% |
| Portage Biotech Inc. | -4.98 Million USD | 65.388% |
| Cardio Diagnostics Holdings, Inc. | -22.49 Thousand USD | -7563.925% |
| Olema Pharmaceuticals, Inc. | -66.12 Million USD | 97.393% |
| OncoCyte Corporation | -6.56 Million USD | 73.732% |
| Qualigen Therapeutics, Inc. | 897.41 Thousand USD | 292.108% |
| Processa Pharmaceuticals, Inc. | -4.55 Million USD | 62.157% |
| Purple Biotech Ltd. | -14.13 Million USD | 87.806% |
| CollPlant Biotechnologies Ltd. | -23.75 Million USD | 92.743% |
| scPharmaceuticals Inc. | -6.54 Million USD | 73.659% |
| ProMIS Neurosciences, Inc. | -16.69 Million USD | 89.672% |
| HilleVax, Inc. | -165.48 Million USD | 98.958% |
| NeuroSense Therapeutics Ltd. | -2.53 Million USD | 32.072% |
| Tharimmune, Inc. | -10.93 Million USD | 84.235% |
| Genprex, Inc. | -6.73 Million USD | 74.412% |
| Neumora Therapeutics, Inc. Common Stock | -368.8 Million USD | 99.533% |
| Atossa Therapeutics, Inc. | -88.46 Million USD | 98.051% |
| XTL Biopharmaceuticals Ltd. | -1.4 Million USD | -23.055% |
| Virios Therapeutics, Inc. | -3.31 Million USD | 48.024% |
| OKYO Pharma Limited | -826.84 Thousand USD | -108.503% |
| Savara Inc. | 153 Thousand USD | 1226.797% |
| Curis, Inc. | -23.88 Million USD | 92.783% |
| Daré Bioscience, Inc. | -5.15 Million USD | 66.576% |
| Carmell Therapeutics Corporation | -776.01 Thousand USD | -122.162% |
| Titan Pharmaceuticals, Inc. | -6.2 Million USD | 72.229% |
| Achieve Life Sciences, Inc. | 1.18 Million USD | 245.485% |
| BeiGene, Ltd. | -2.25 Billion USD | 99.923% |
| Kiromic BioPharma, Inc. | 12.33 Million USD | 113.973% |
| Revolution Medicines, Inc. Warrant | -608.2 Million USD | 99.717% |
| Protagonist Therapeutics, Inc. | -185.58 Million USD | 99.071% |
| Erasca, Inc. | -37.21 Million USD | 95.368% |
| bluebird bio, Inc. | 108.57 Million USD | 101.588% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -33.862% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 100.455% |
| DBV Technologies S.A. | -126.98 Million USD | 98.642% |
| Protagenic Therapeutics, Inc. | -1.28 Million USD | -33.862% |
| Moderna, Inc. | -2.9 Billion USD | 99.941% |
| Vincerx Pharma, Inc. | -10.35 Million USD | 83.346% |
| Fresh Tracks Therapeutics, Inc. | -10.86 Million USD | 84.137% |
| Molecular Templates, Inc. | 707 Thousand USD | 343.847% |
| Acrivon Therapeutics, Inc. Common Stock | -31.37 Million USD | 94.504% |
| Travere Therapeutics, Inc. | 346.6 Million USD | 100.497% |
| Monte Rosa Therapeutics, Inc. | -82.06 Million USD | 97.899% |
| Spruce Biosciences, Inc. | -91.73 Million USD | 98.121% |
| Celldex Therapeutics, Inc. | -32.27 Million USD | 94.658% |
| Cogent Biosciences, Inc. | -34.37 Million USD | 94.985% |
| MacroGenics, Inc. | -66.98 Million USD | 97.426% |
| RenovoRx, Inc. | -1.17 Million USD | -46.974% |
| Adicet Bio, Inc. | -138.78 Million USD | 98.758% |
| Prime Medicine, Inc. | -27.94 Million USD | 93.83% |
| Aditxt, Inc. | 18.12 Million USD | 109.514% |
| Adagene Inc. | -87.62 Million USD | 98.033% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 58.612% |
| Quantum-Si incorporated | -118.55 Million USD | 98.546% |
| Maravai LifeSciences Holdings, Inc. | 36 Million USD | 104.788% |
| Acurx Pharmaceuticals, Inc. | -7.47 Million USD | 76.934% |
| Voyager Therapeutics, Inc. | -48.5 Million USD | 96.446% |
| SciSparc Ltd. | -2.06 Million USD | 16.513% |
| Vericel Corporation | 1.27 Million USD | 235.004% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 85.623% |
| Minerva Neurosciences, Inc. | 41 Million USD | 104.204% |
| Generation Bio Co. | 31.44 Million USD | 105.482% |
| Astria Therapeutics, Inc. | -175.36 Million USD | 99.017% |
| Black Diamond Therapeutics, Inc. | -30.92 Million USD | 94.425% |
| Arcutis Biotherapeutics, Inc. | 116.59 Million USD | 101.479% |
| Invivyd, Inc. | -198.47 Million USD | 99.131% |
| Relay Therapeutics, Inc. | -90.27 Million USD | 98.09% |
| Quoin Pharmaceuticals, Ltd. | -2.39 Million USD | 28.097% |
| Spero Therapeutics, Inc. | -70.79 Million USD | 97.565% |
| Artelo Biosciences, Inc. | -6.82 Million USD | 74.74% |
| 2seventy bio, Inc. | 181.71 Million USD | 100.949% |
| ADMA Biologics, Inc. | 90.06 Million USD | 101.914% |
| Clene Inc. | 3.34 Million USD | 151.617% |
| Capricor Therapeutics, Inc. | -9.08 Million USD | 81.019% |
| Boundless Bio, Inc. Common Stock | -21.51 Million USD | 91.985% |
| GeoVax Labs, Inc. | -6.45 Million USD | 73.282% |
| Recursion Pharmaceuticals, Inc. | -344.12 Million USD | 99.499% |
| Citius Pharmaceuticals, Inc. | -25.99 Million USD | 93.369% |
| Contineum Therapeutics, Inc. Class A Common Stock | 177.66 Million USD | 100.97% |
| Relmada Therapeutics, Inc. | -4.09 Million USD | 57.865% |
| Finch Therapeutics Group, Inc. | 5 Million USD | 134.466% |
| ALX Oncology Holdings Inc. | -5.2 Million USD | 66.903% |
| Vir Biotechnology, Inc. | -130.3 Million USD | 98.677% |
| Evaxion Biotech A/S | 5.28 Million USD | 132.609% |
| Ocular Therapeutix, Inc. | -112.56 Million USD | 98.468% |
| Verve Therapeutics, Inc. | -131.27 Million USD | 98.687% |
| Trevena, Inc. | 2.25 Million USD | 176.351% |
| Surrozen, Inc. | -32.66 Million USD | 94.722% |
| Tyra Biosciences, Inc. | -51.51 Million USD | 96.653% |
| Cingulate Inc. | 3.08 Million USD | 155.925% |
| Galmed Pharmaceuticals Ltd. | -2.93 Million USD | 41.301% |
| Unity Biotechnology, Inc. | 7.18 Million USD | 123.988% |
| Tenax Therapeutics, Inc. | -9.29 Million USD | 81.445% |
| Terns Pharmaceuticals, Inc. | -79.32 Million USD | 97.827% |
| ACADIA Pharmaceuticals Inc. | -131.45 Million USD | 98.688% |
| Connect Biopharma Holdings Limited | -105.54 Million USD | 98.367% |
| Clearmind Medicine Inc. | -3.94 Million USD | 56.273% |
| Kronos Bio, Inc. | -36.05 Million USD | 95.218% |
| Bolt Biotherapeutics, Inc. | 9.4 Million USD | 118.323% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 218.234% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 96.822% |
| Statera Biopharma, Inc. | 14.41 Million USD | 111.959% |
| ImmunityBio, Inc. | 618.22 Million USD | 100.279% |
| Korro Bio, Inc. | -132.94 Million USD | 98.703% |
| Kineta, Inc. | -4.54 Million USD | 62.035% |
| BioVie Inc. | -17.73 Million USD | 90.278% |
| Codexis, Inc. | -43.27 Million USD | 96.016% |
| Celularity Inc. | 65.19 Million USD | 102.645% |
| Crinetics Pharmaceuticals, Inc. | -3.16 Million USD | 45.598% |
| Celcuity Inc. | 6.78 Million USD | 125.415% |
| Virax Biolabs Group Limited | -3.36 Million USD | 48.766% |
| Cibus, Inc. | -8.07 Million USD | 78.658% |
| Eledon Pharmaceuticals, Inc. | -4.22 Million USD | 59.234% |
| eFFECTOR Therapeutics, Inc. | 4.57 Million USD | 137.724% |
| IN8bio, Inc. | -16.38 Million USD | 89.481% |
| Kodiak Sciences Inc. | -103.87 Million USD | 98.34% |
| Annexon, Inc. | -193.75 Million USD | 99.11% |
| Adverum Biotechnologies, Inc. | 36 Thousand USD | 4888.889% |
| Assembly Biosciences, Inc. | -17.49 Million USD | 90.148% |
| Avalo Therapeutics, Inc. | -3.51 Million USD | 50.925% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 100.164% |
| Eyenovia, Inc. | 1.25 Million USD | 236.966% |
| Puma Biotechnology, Inc. | 26.9 Million USD | 106.408% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 46.839% |
| Xilio Therapeutics, Inc. | -33.24 Million USD | 94.815% |
| Arcellx, Inc. | -296.95 Million USD | 99.419% |
| Cardiff Oncology, Inc. | -19.5 Million USD | 91.162% |
| Enanta Pharmaceuticals, Inc. | -58.87 Million USD | 97.072% |
| Regulus Therapeutics Inc. | -20.72 Million USD | 91.682% |
| Moolec Science SA | 117.61 Thousand USD | 1565.787% |
| Acumen Pharmaceuticals, Inc. | -38.39 Million USD | 95.51% |
| Geron Corporation | 14.76 Million USD | 111.679% |
| LAVA Therapeutics N.V. | -37.91 Million USD | 95.453% |
| Royalty Pharma plc | 5.65 Billion USD | 100.03% |
| Atea Pharmaceuticals, Inc. | -141.42 Million USD | 98.781% |
| Greenwich LifeSciences, Inc. | -6.98 Million USD | 75.334% |
| TFF Pharmaceuticals, Inc. | -5.36 Million USD | 67.853% |
| Mersana Therapeutics, Inc. | -140.73 Million USD | 98.775% |
| Humacyte, Inc. | -22.48 Million USD | 92.333% |
| Structure Therapeutics Inc. | -124.33 Million USD | 98.613% |
| 89bio, Inc. | -289.05 Million USD | 99.404% |
| PMV Pharmaceuticals, Inc. | -25.24 Million USD | 93.17% |
| Avenue Therapeutics, Inc. | -1.78 Million USD | 3.309% |
| Genelux Corporation | -6.89 Million USD | 75.011% |
| Trevi Therapeutics, Inc. | -31.05 Million USD | 94.449% |
| Lexicon Pharmaceuticals, Inc. | 83.59 Million USD | 102.062% |
| Notable Labs, Ltd. | -9.77 Million USD | 82.365% |
| Liquidia Corporation | -80.17 Million USD | 97.85% |
| Mustang Bio, Inc. | -3.73 Million USD | 53.854% |
| Immunovant, Inc. | -635.22 Million USD | 99.729% |
| Quantum-Si incorporated | -118.55 Million USD | 98.546% |
| Arbutus Biopharma Corporation | -17.56 Million USD | 90.184% |
| DiaMedica Therapeutics Inc. | -4.14 Million USD | 58.388% |
| Vera Therapeutics, Inc. | 8.02 Million USD | 121.478% |
| Acasti Pharma Inc. | -23 Million USD | 92.506% |
| MiNK Therapeutics, Inc. | -3.36 Million USD | 48.801% |
| Pasithea Therapeutics Corp. | -16.24 Million USD | 89.39% |
| Xenon Pharmaceuticals Inc. | -137.74 Million USD | 98.748% |
| Elevai Labs, Inc. Common Stock | -3.11 Million USD | 44.679% |
| NeuroBo Pharmaceuticals, Inc. | -22.23 Million USD | 92.245% |
| Tempest Therapeutics, Inc. | -18.56 Million USD | 90.716% |
| Soleno Therapeutics, Inc. | -169.27 Million USD | 98.982% |
| PepGen Inc. | -60.67 Million USD | 97.158% |
| Moleculin Biotech, Inc. | -22.97 Million USD | 92.497% |
| United Therapeutics Corporation | -507.7 Million USD | 99.66% |
| Nuvectis Pharma, Inc. | -19.12 Million USD | 90.986% |
| Solid Biosciences Inc. | -47.75 Million USD | 96.39% |
| BriaCell Therapeutics Corp. | -862.08 Thousand USD | -99.979% |
| Immuneering Corporation | -54.94 Million USD | 96.862% |
| Lixte Biotechnology Holdings, Inc. | -4.2 Million USD | 58.986% |
| Silo Pharma, Inc. | -3.52 Million USD | 51.083% |
| Belite Bio, Inc | -87.27 Million USD | 98.025% |
| XOMA Corporation | -29 Million USD | 94.055% |
| ARS Pharmaceuticals, Inc. | -70.69 Million USD | 97.561% |
| Bionomics Limited | 227 Million USD | 100.759% |
| Apogee Therapeutics, Inc. | -116.28 Million USD | 98.517% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 31.938% |
| uniQure N.V. | -102.95 Million USD | 98.325% |
| Cassava Sciences, Inc. | -121.13 Million USD | 98.577% |
| Estrella Immunopharma, Inc. | -4.16 Million USD | 58.612% |
| Poseida Therapeutics, Inc. | 40.95 Million USD | 104.21% |
| Forte Biosciences, Inc. | -11.96 Million USD | 85.586% |
| Anebulo Pharmaceuticals, Inc. | -3.09 Million USD | 44.283% |
| Enlivex Therapeutics Ltd. | 106 Thousand USD | 1726.415% |
| Conduit Pharmaceuticals Inc. | -3.24 Million USD | 46.839% |
| SeaStar Medical Holding Corporation | 8.9 Million USD | 119.36% |
| FibroBiologics, Inc. Common Stock | -7.41 Million USD | 76.753% |
| Altimmune, Inc. | -134.48 Million USD | 98.718% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 100.87% |
| Alpha Tau Medical Ltd. | -2.53 Million USD | 31.938% |
| Compugen Ltd. | -12.9 Million USD | 86.64% |
| Peak Bio, Inc. | 10.34 Million USD | 116.673% |
| Zevra Therapeutics, Inc. | -283 Thousand USD | -509.187% |
| Benitec Biopharma Inc. | -50.58 Million USD | 96.592% |
| Spyre Therapeutics, Inc. | -104.33 Million USD | 98.348% |
| NKGen Biotech, Inc. Common Stock | 19.64 Million USD | 108.776% |
| Zura Bio Limited | -99.8 Million USD | 98.273% |
| PolyPid Ltd. | 6.17 Million USD | 127.942% |
| Aileron Therapeutics, Inc. | 74.12 Million USD | 102.326% |
| NKGen Biotech, Inc. Warrants | 19.64 Million USD | 108.776% |
| Instil Bio, Inc. | 75.35 Million USD | 102.288% |
| argenx SE | -2.02 Billion USD | 99.915% |
| Immunome, Inc. | -97.02 Million USD | 98.223% |
| Compass Therapeutics, Inc. | -22.49 Million USD | 92.336% |
| Verona Pharma plc | -220.44 Million USD | 99.218% |
| enGene Holdings Inc. Warrants | -71.74 Million USD | 97.597% |
| Shattuck Labs, Inc. | -121.42 Million USD | 98.58% |
| CervoMed Inc. | -7.79 Million USD | 77.877% |
| LENZ Therapeutics, Inc. | -185.49 Million USD | 99.071% |
| Plus Therapeutics, Inc. | -4.37 Million USD | 60.576% |
| Dianthus Therapeutics, Inc. | -131.73 Million USD | 98.691% |
| Moolec Science SA | 117.61 Thousand USD | 1565.787% |
| Enveric Biosciences, Inc. | -2.28 Million USD | 24.65% |
| Inovio Pharmaceuticals, Inc. | 15.89 Million USD | 110.844% |
| AnaptysBio, Inc. | -18.15 Million USD | 90.502% |
| Design Therapeutics, Inc. | -18.15 Million USD | 90.501% |
| Leap Therapeutics, Inc. | -70.38 Million USD | 97.55% |
| NeurAxis, Inc. | 145.7 Thousand USD | 1283.253% |
| Seelos Therapeutics, Inc. | 11.23 Million USD | 115.349% |
| Lumos Pharma, Inc. | -28.49 Million USD | 93.949% |
| Achilles Therapeutics plc | -126.92 Million USD | 98.642% |
| enGene Holdings Inc. Common Stock | -71.74 Million USD | 97.597% |
| 180 Life Sciences Corp. | -655.73 Thousand USD | -162.913% |
| Opiant Pharmaceuticals, Inc. | -20.77 Million USD | 91.701% |
| CERo Therapeutics Holdings, Inc. | 1.45 Million USD | 218.234% |
| Nutriband Inc. | -251.65 Thousand USD | -585.059% |
| ORIC Pharmaceuticals, Inc. | -13.17 Million USD | 86.911% |
| CG Oncology, Inc. Common stock | -7.44 Million USD | 76.828% |
| Fractyl Health, Inc. Common Stock | 340.19 Million USD | 100.507% |
| Rani Therapeutics Holdings, Inc. | 23.73 Million USD | 107.264% |
| MoonLake Immunotherapeutics | -447.47 Million USD | 99.615% |
| Palisade Bio, Inc. | -12.06 Million USD | 85.708% |
| Tourmaline Bio, Inc. | -140.31 Million USD | 98.771% |
| Beam Therapeutics Inc. | -262.72 Million USD | 99.344% |
| Neurogene Inc. | -131.95 Million USD | 98.693% |
| Mirum Pharmaceuticals, Inc. | 21.81 Million USD | 107.902% |
| AEON Biopharma, Inc. | -4.88 Million USD | 64.672% |
| CARGO Therapeutics, Inc. Common Stock | -377.19 Million USD | 99.543% |
| Sesen Bio, Inc. | -112.55 Million USD | 98.468% |
| Enliven Therapeutics, Inc. | -99.86 Million USD | 98.274% |
| Kiora Pharmaceuticals, Inc. | -2.34 Million USD | 26.569% |
| Iovance Biotherapeutics, Inc. | -39.02 Million USD | 95.582% |
| Taysha Gene Therapies, Inc. | -83.28 Million USD | 97.93% |
| Athira Pharma, Inc. | -88.99 Million USD | 98.063% |
| Vaccinex, Inc. | -1.28 Million USD | -33.851% |
| HCW Biologics Inc. | 2.85 Million USD | 160.35% |
| XOMA Corporation | -29 Million USD | 94.055% |
| Nektar Therapeutics | 210.24 Million USD | 100.82% |
| Arvinas, Inc. | -313.8 Million USD | 99.451% |
| Tevogen Bio Holdings Inc. | 1.62 Million USD | 206.23% |
| Merus N.V. | -192.88 Million USD | 99.106% |
| Omega Therapeutics, Inc. | 59.98 Million USD | 102.874% |
| Quince Therapeutics, Inc. | -6.93 Million USD | 75.151% |
| Rezolute, Inc. | -68.16 Million USD | 97.471% |
| Clene Inc. | 3.34 Million USD | 151.617% |
| Indaptus Therapeutics, Inc. | -13.18 Million USD | 86.927% |
| BeyondSpring Inc. | -13.75 Million USD | 87.466% |
| Synlogic, Inc. | -6.68 Million USD | 74.211% |
| Allarity Therapeutics, Inc. | 1.13 Million USD | 252.028% |
| Phio Pharmaceuticals Corp. | -8.45 Million USD | 79.61% |
| Peak Bio, Inc. | 10.34 Million USD | 116.673% |
| Werewolf Therapeutics, Inc. | -82.42 Million USD | 97.908% |
| Krystal Biotech, Inc. | -350.23 Million USD | 99.508% |
| Karyopharm Therapeutics Inc. | 124.12 Million USD | 101.389% |
| SpringWorks Therapeutics, Inc. | -168.99 Million USD | 98.98% |
| Lipella Pharmaceuticals Inc. | -3.15 Million USD | 45.394% |
| MannKind Corporation | 143.89 Million USD | 101.198% |
| Ikena Oncology, Inc. | -109.15 Million USD | 98.421% |
| Cyclerion Therapeutics, Inc. | -7.57 Million USD | 77.229% |
| Gyre Therapeutics, Inc. | -33.1 Million USD | 94.792% |
| Gossamer Bio, Inc. | 180.35 Million USD | 100.956% |
| CohBar, Inc. | -5.93 Million USD | 70.931% |
| Cognition Therapeutics, Inc. | -29.74 Million USD | 94.205% |
| NRx Pharmaceuticals, Inc. | 4.56 Million USD | 137.757% |
| Legend Biotech Corporation | -949.39 Million USD | 99.818% |
| Mural Oncology plc | -255.84 Million USD | 99.326% |
| Biora Therapeutics, Inc. | 32.21 Million USD | 105.352% |
| PaxMedica, Inc. Common Stock | -4.71 Million USD | 63.402% |
| Disc Medicine, Inc. | -358.28 Million USD | 99.519% |
| Champions Oncology, Inc. | 4.81 Million USD | 135.827% |
| REGENXBIO Inc. | 54.76 Million USD | 103.148% |
| Ensysce Biosciences, Inc. | -268.9 Thousand USD | -541.114% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 98.858% |
| Cellectar Biosciences, Inc. | -9.01 Million USD | 80.87% |
| Edgewise Therapeutics, Inc. | -80.68 Million USD | 97.863% |
| Vaxart, Inc. | -8.24 Million USD | 79.08% |
| PharmaCyte Biotech, Inc. | -50.17 Million USD | 96.564% |
| Aldeyra Therapeutics, Inc. | -127.16 Million USD | 98.644% |
| Cellectis S.A. | -43.85 Million USD | 96.069% |
| Longeveron Inc. | -2.9 Million USD | 40.715% |
| Repare Therapeutics Inc. | -107.85 Million USD | 98.402% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 100.178% |
| Inozyme Pharma, Inc. | 12 Million USD | 114.362% |
| Revolution Medicines, Inc. | -608.2 Million USD | 99.717% |
| Nymox Pharmaceutical Corporation | -1.23 Million USD | -40.163% |
| Third Harmonic Bio, Inc. | -265.11 Million USD | 99.35% |
| ArriVent BioPharma, Inc. Common Stock | -150.07 Million USD | 98.851% |
| AN2 Therapeutics, Inc. | -15.64 Million USD | 88.982% |
| Anixa Biosciences, Inc. | -740 Thousand USD | -132.973% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 99.982% |
| Denali Therapeutics Inc. | -74.86 Million USD | 97.697% |
| Revelation Biosciences, Inc. | -11.99 Million USD | 85.623% |
| Veru Inc. | 4.77 Million USD | 136.067% |
| Corvus Pharmaceuticals, Inc. | -11.24 Million USD | 84.67% |
| Cingulate Inc. | 3.08 Million USD | 155.925% |
| Passage Bio, Inc. | 4.58 Million USD | 137.601% |
| Context Therapeutics Inc. | -14.44 Million USD | 88.069% |
| Exicure, Inc. | 5.84 Million USD | 129.475% |
| Day One Biopharmaceuticals, Inc. | -230.37 Million USD | 99.252% |
| Oramed Pharmaceuticals Inc. | -39.57 Million USD | 95.643% |
| Scinai Immunotherapeutics Ltd. | 15.69 Million USD | 110.987% |
| Rhythm Pharmaceuticals, Inc. | -58.82 Million USD | 97.069% |
| Nuvalent, Inc. | -335.38 Million USD | 99.486% |
| ABVC BioPharma, Inc. | 1.73 Million USD | 199.404% |
| Carisma Therapeutics, Inc. | -74.48 Million USD | 97.685% |
| Unicycive Therapeutics, Inc. | -8.89 Million USD | 80.607% |
| OmniAb, Inc. | 9.2 Million USD | 118.733% |
| Anew Medical, Inc. | 1.43 Million USD | 220.352% |
| Fennec Pharmaceuticals Inc. | 16.38 Million USD | 110.524% |
| Lipocine Inc. | -4.75 Million USD | 63.74% |
| Lexeo Therapeutics, Inc. Common Stock | -109.82 Million USD | 98.43% |
| Nautilus Biotechnology, Inc. | 15.23 Million USD | 111.319% |
| SAB Biotherapeutics, Inc. | -50.65 Million USD | 96.597% |
| G1 Therapeutics, Inc. | 24.89 Million USD | 106.926% |
| Bellerophon Therapeutics, Inc. | -6.72 Million USD | 74.349% |
| Sage Therapeutics, Inc. | -65.82 Million USD | 97.381% |
| Ocugen, Inc. | -32.52 Million USD | 94.699% |
| Mind Medicine (MindMed) Inc. | -85.57 Million USD | 97.985% |
| Q32 Bio Inc. | -37.94 Million USD | 95.457% |
| Brainstorm Cell Therapeutics Inc. | -628 Thousand USD | -174.522% |
| Alumis Inc. Common Stock | -13.52 Million USD | 87.257% |
| Equillium, Inc. | -22.39 Million USD | 92.301% |
| Kyverna Therapeutics, Inc. | -25.56 Million USD | 93.257% |
| Coya Therapeutics, Inc. | -32.62 Million USD | 94.716% |
| CNS Pharmaceuticals, Inc. | -247.91 Thousand USD | -595.4% |
| Galera Therapeutics, Inc. | 134.04 Million USD | 101.286% |
| Evelo Biosciences, Inc. | 3.19 Million USD | 153.909% |
| Comera Life Sciences Holdings, Inc. | 328.44 Thousand USD | 624.904% |
| Dominari Holdings Inc. | 195 Thousand USD | 984.103% |
| Edesa Biotech, Inc. | -5.26 Million USD | 67.267% |
| vTv Therapeutics Inc. | -8.91 Million USD | 80.666% |
| Bio-Techne Corporation | 267.74 Million USD | 100.644% |
| Agios Pharmaceuticals, Inc. | -16.2 Million USD | 89.364% |
| Harmony Biosciences Holdings, Inc. | -118.09 Million USD | 98.54% |
| Prelude Therapeutics Incorporated | -8.4 Million USD | 79.484% |
| Candel Therapeutics, Inc. | -12.65 Million USD | 86.373% |
| iTeos Therapeutics, Inc. | -245.11 Million USD | 99.297% |
| Nkarta, Inc. | 57.29 Million USD | 103.009% |
| BioCardia, Inc. | 212 Thousand USD | 913.208% |
| Iterum Therapeutics plc | 13.43 Million USD | 112.829% |